|
Tasly
Pharmaceutical Group and Trigen Pharma are in joint venture to
market and produce over 100 medicines which include numerous
high profile research based medicines in Pakistan including
their blockbuster medicine TriCardin.
Trigen and Tasly
are also jointly collaborating on many other fronts including
establishing scientific relationships between Tasly
Microcirculation Research Center at Peking University and
leading institutions of Pakistan. Other projects include joint
research and development collaboration between prestigious
medical universities of Pakistan and Peking University.
Tasly
Pharmaceutical Group was founded in 1994 in China. It is
listed on the Shanghai Stock Exchange. Tasly Pharma Group’s
core focus is on scientific research and development to “share
the joy of health with all”. Tasly’s strong R&D in joint
development projects with the world’s leading
universities/research centers has led to the creation of a
robust and innovative product pipeline.
During the years
Tasly has launched many blockbuster medicines including
TriCardin. Our unprecedented success and breakneck growth rate
has enabled us to expand from phytopharmaceutical medicines to
chemical pharmaceutical production, biotech products amid
rapid market expansion. Its tremendous growth over the last 15
years is illustrated by its exponential annual growth rate of
more than 90%, while the total assets of the Group are fast
multiplying at 100 times.
Crowned with the
name of Tasly Modern TCM Garden, China’s largest
pharmaceutical enterprise’s headquarters is located in the
city of Tianjin and occupies 200,000 square meters of area. It
has four state of the art factories, hi-tech R&D labs and 21st
Century Biotech labs.
We have more than
80 branch offices in China, subsidiaries in more than 40
regions of China and presence in more than 34 countries
including USA, France, Finland, Canada, Thailand, Japan,
Singapore, Malaysia, UAE, Vietnam, Russia, Netherlands, South
Korea, South Africa and Australia.
Tasly has grown
rapidly in terms of pharmaceutical and medicinal
manufacturing; natural herb medicine research and cultivation;
standardized planting; processing and production related high
technology. This is the place where highly educated talents of
various disciplines merge and diligently work on the
modernization of Chinese medicine and towards the growth of
the group.
Tasly has won
numerous accolades and awards for its efforts including FDA
IND, GMP, GAP, GLP, GEP, SGS (Switzerland), TGA (Australia),
ISO 14001, BSI (UK), Reward of National Technology
Advancement, The Hundred Most Strong Medicine Enterprise and
the Most Vital Enterprise in China among others.
Tasly
Pharmaceutical Group major milestones:
- Tasly’s first
and flagship product
TriCardin (Fu Fang Dan Shen Di Wan) is
the highest selling single medicine in China’s Pharmaceutical
Industry.
- TriCardin (Fu
Fang Dan Shen Di Wan) is the highest selling medicine in
China’s cardiology sector.
- Tasly is the
first group in China that set up herbal plantation bases in
full compliance with international standards Good Agricultural
Practice (GAP).
- Tasly is the
first group in China to be endowed with the accolade of “a
modern industry of modernization of Chinese Herbal Medicine
enterprise.”
- The colossal
structure of Tasly Group set up at its head office displaying
the rich historical background spanning 5,000 years of the
development of Chinese Medicine in China; has now garnered a
place in the Guinness World Records.
- Tasly is the
first group to introduce the new concept of Good Extraction
Practice (GEP) for standardization, digitalization and
industrialization of Traditional Chinese Medicine.
- At the
beginning of 1997, State Scientific Committee of China
selected
TriCardin (Fu Fang Dan Shen Di Wan) to register at US
FDA, which was granted US FDA status on September 29, 1998
(FDA IND No. 56956)
Tasly
Microcirculation Research Center is located in Peking
University which offers a Post Doctoral/Post Graduate Program
for higher education; and has joint Research and Development
collaboration with Harvard University (USA), Aston University
(UK), Baker Lab (Australia), Monash University (Australia),
Keio University (Japan), Zhejinang University (China), Peking
University (China).
Tasly is the
undisputed leader in the field of microcirculation research
and solution.s
A brief glimpse of Tasly Headquarters, facilities, R&D Centre, Tasly Insititute etc.
|
